The genetic adaptability part of the equation is what worries me. Cells can all too easily adapt for survival. If this works it is a breakthrough, but I’m afraid that it won’t stand the test of time and mutation over the many forms of cancer.
With a DNA/RNA approach, it doesn't matter. The treatment drug is tailored to the specific genetic makeup of the specific individual being treated, and the specific mutation that is causing their disease.
If you work at the RNA level, I think it can work on all mutations. More to come...